RESUMO
The results suggest that addition of pioglitazone in a complex treatment therapy of patients with ischemic heart disease on background of metabolic syndrome was not associated with an increased ischemic heart disease (IHD) risk and improved the clinical course of IHD, increased effectiveness of standard therapy for patients with IHD and metabolic syndrome.
Assuntos
Combinação de Medicamentos , Síndrome Metabólica/tratamento farmacológico , Isquemia Miocárdica/tratamento farmacológico , Tiazolidinedionas , Idoso , Anlodipino/administração & dosagem , Aspirina/administração & dosagem , Atorvastatina , Biomarcadores/sangue , Biomarcadores/urina , Bisoprolol/administração & dosagem , Pressão Sanguínea , Índice de Massa Corporal , Feminino , Ácidos Heptanoicos/administração & dosagem , Humanos , Dinitrato de Isossorbida/administração & dosagem , Masculino , Síndrome Metabólica/sangue , Síndrome Metabólica/complicações , Síndrome Metabólica/fisiopatologia , Síndrome Metabólica/urina , Pessoa de Meia-Idade , Isquemia Miocárdica/sangue , Isquemia Miocárdica/complicações , Isquemia Miocárdica/fisiopatologia , Isquemia Miocárdica/urina , Obesidade/complicações , Pioglitazona , Pirróis/administração & dosagem , Fatores de Risco , Fumar/efeitos adversos , Tiazolidinedionas/administração & dosagem , Tiazolidinedionas/uso terapêutico , Resultado do TratamentoRESUMO
We investigated the effectiveness of pioglitazone in the treatment of patients with coronary heart disease in combination with MS. In the conduct of research revealed that the addition to standard therapy in patients with coronary heart disease on the background of metabolic syndrome pioglitazone led to a reliable slight decrease in body weight, BMI, hip circumference, waist their relationship. Receiving pioglitazone also significantly reduces the concentration of immunoreactive insulin and blood glucose levels, significantly altered lipid metabolism, which generally leads to a lower level of systemic inflammation, metabolism and reduces the severity of insulin resistance. This allows you to recommend the inclusion of pioglitazone in complex coronary heart disease and metabolic syndrome.